Related Experiment Video
Updated: Aug 10, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
Pegaptanib for neovascular age-related macular degeneration
Abstract:
(1) Neovascular (wet) age-related macular degeneration (AMD) results from the growth of abnormal blood vessels under the retina (choroidal neovascularization). Sudden and permanent vision loss occurs as these vessels grow, leak, bleed, and scar. (2) A human protein, vascular endothelial growth factor (VEGF), is implicated in the development of wet AMD. Pegaptanib attaches to VEGF and blocks its action. (3) In two concurrent, high quality studies using identical research methods, pegaptanib demonstrated a therapeutic advantage over placebo for the prevention of vision loss due to neovascular AMD. (4) Pegaptanib is injected into the eye every six weeks. This carries the risk of endophthalmitis (intraocular infection), lens damage (if accidentally penetrated), and retinal detachment. Systemic side-effects have not been associated with pegaptanib.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy
Glaucoma: Overview